title: Decrease of B-cells and autoantibodies after low-dose methotrexate.
abstract: The purpose was to assess the efficacy of low-dose methotrexate (MTX) on immunological parameters in patients with lupus erythematosus (LE) under short- (</=10 weeks) vs. long-term (>10 weeks) conditions. Patients who did not respond to classical LE treatment (antimalarials and/or glucocorticosteroids) were retrospectively analyzed. Twenty-two LE-patients received 10-30 mg MTX per week. Sera and ethylenediaminetetra-acetic blood specimens were analyzed for autoantibodies and lymphocyte subsets (flow cytometry), respectively. Clinical improvement occurred in 21 patients (complete response n = 15, 68.2%). B-cells were the main targets: their absolute number significantly dropped down after long-term treatment (290 +/- 49 vs. 221 +/- 41 microl(-1), P = 0.00254). This was accompanied by down-regulation of autoantibodies. The effect on B-cells was more pronounced in patients with (before vs. long-term 172 +/- 34 vs. 99 +/- 15 microl(-1), P = 0.02853) than without autoantibodies (169 +/- 40 vs. 144 +/- 51 microl(-1), P = 0.55406). MTX did not induce immunosuppression. Low-dose MTX has different short- and long-term effects on immunologic parameters, which could explain the clinical improvement.
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D001323:Autoantibodies / Q000097:blood / Q000276:immunology*; D001402:B-Lymphocytes / Q000166:cytology / Q000276:immunology*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008178:Lupus Erythematosus, Cutaneous / Q000097:blood / Q000188:drug therapy* / Q000276:immunology; D008180:Lupus Erythematosus, Systemic / Q000097:blood / Q000188:drug therapy* / Q000276:immunology; D018655:Lymphocyte Count; D016131:Lymphocyte Subsets / Q000166:cytology / Q000276:immunology; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage / Q000627:therapeutic use*; D008875:Middle Aged; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D000276:Adjuvants, Immunologic; D001323:Autoantibodies; D008727:Methotrexate